I have to disagree sarge.
Any potential licensee would surely look at Starpharma's revenue figures over the last few years and quickly figure that they have been sub ordinary to say the least. So why would anyone pay for the opportunity to take on the license knowing that they will be the responsible party for any future success.
They are starting from a very low base, much lower than with the initial launch.
- Forums
- ASX - By Stock
- SPL
- Ann: VivaGel BV sales and distribution agreement MENA region
Ann: VivaGel BV sales and distribution agreement MENA region, page-24
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SPL (ASX) to my watchlist
(20min delay)
|
|||||
Last
9.8¢ |
Change
0.001(1.03%) |
Mkt cap ! $40.90M |
Open | High | Low | Value | Volume |
9.5¢ | 9.8¢ | 9.5¢ | $3.089K | 31.87K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 58131 | 9.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
10.0¢ | 34876 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 58131 | 0.096 |
3 | 308325 | 0.095 |
4 | 360000 | 0.094 |
2 | 9659 | 0.093 |
2 | 134306 | 0.092 |
Price($) | Vol. | No. |
---|---|---|
0.100 | 34876 | 2 |
0.105 | 209291 | 3 |
0.110 | 168286 | 9 |
0.115 | 85453 | 2 |
0.120 | 79405 | 9 |
Last trade - 16.10pm 07/10/2024 (20 minute delay) ? |
Featured News
SPL (ASX) Chart |